Page 98 - Read Online
P. 98

Correnti et al. Hepatoma Res 2018;4:69  I  http://dx.doi.org/10.20517/2394-5079.2018.96                                           Page 3 of 15


               According to this model, CSCs represent a fraction of cells resident in the tumor endowed with stem-
               like features like the ability to self-renew and differentiate into heterogeneous tumor cell progeny as well
               as with the unresponsiveness to treatments [52,53] , and represent the unit of selection within the tumor,
                                                                  [50]
               while any other bulk tumor cells lead to clonal exhaustion . More importantly, CSCs are thought to be
               a unique cellular subset responsible not only for tumor initiation but also for tumor growth maintenance,
               tumor recurrence and metastasis, showing intrinsic resistance to chemotherapeutic drugs compared to
               bulk tumor cells [52,54-56] . In this view, the existence of CSCs represent an entirely distinct dimension of
                                       [57]
               intra-tumoral heterogeneity .

               Interestingly, a third model has been recently proposed to explain the intra-tumor heterogeneity, the
               so-called “CSC plasticity model”. According with this theory, tumor cells represent a very plastic and
               dynamic population, with the ability to continuously shift between non-CSC and CSC states, in response
               to intrinsic and extrinsic stimuli. In this view, the stochastic and the CSC model not only are not mutually
                                                                                           [58]
               exclusive, but can be integrated with each other, adding a new level of tumor complexity .

               The idea that tumor initiation and progression are driven by stem-like cells is still a subject of debate,
                                             [59]
               since the first time it was proposed  until today. While CSC existence has been confirmed in a growing
               range of hematologic and solid tumors (e.g., acute myeloid leukemia, pancreatic cancer, breast cancer, lung
               cancer, hepatocellular carcinoma, head and neck cancer, colon cancer, prostate cancer, melanoma, and
                                                                                           [60]
               glioblastoma), no agreement has yet been reached regarding the origin of putative CSCs . Some reports
               have indicated that CSCs can originate from normal resident stem cells, due to their inherent self-renewal
               capacity and long life span that can allow them to accumulate oncogenic and epigenetic modifications,
               resulting in malignant transformation. Alternatively, CSCs may originate from more committed
                             [47]
               progenitor cells , or even from differentiated non-CSCs that re-acquire stem cell properties by de-
               differentiation or reprogramming processes [61,62] . Thus, tumor hierarchical organization does not imply
               that CSCs originated from normal stem cells, and the CSC model does not address the cell-of-origin,
               that represents the normal cell that acquires the first cancer-promoting mutation(s) and is not necessarily
               related to the CSC concept [63,64] . These considerations interconnect with the debate on the true nature of the
               cell-of-origin of PLC. While it has already been accepted that HCC progression is driven by CSCs [22,65-69] , very
                                                                            [71]
                                                               [70]
               few studies have indicated the presence of CSCs in CCA  (reviewed in ).
               REGULATORY PATHWAYS INVOLVED IN PLC-ASSOCIATED STEMNESS
               Many of the identified CSC regulatory pathways are also known to be involved in normal stem-cell
               maintenance as well as in self-renewal potential and pluripotency of embryonic stem cells [72-77] . Here, we
               will briefly review the key regulatory pathways that support stemness features in the context of PLC [Figure 1].


               Wingless-type MMTV integration site family member (Wnt)/β-catenin pathway
               Disruption of Wnt/β-catenin signaling results from both genetic and epigenetic changes in many tumors,
               including PLC. Wnt/β-catenin canonical signaling pathway appears to be involved in stemness main-
               tenance in both embryonic and cancer stem cells [78,79] . Extracellular Wnt ligand binds to Frizzled cell
               surface receptors leading to increased cytoplasmic β-catenin levels, with the following induction of Wnt
               key target genes [31,55,80] . Notably, β-catenin is expressed in 58% of CCA, mutated in 8% of cases and it is
                                                             [71]
               considered an early determinant in CCA-progression . In up to 90% of HCCs, the Wnt receptor FZD-7 is
                                                                                                        [81]
               overexpressed, and 20%-40% of HCCs have unusual cytoplasmic and nuclear accumulation of β-catenin .
               Moreover, in 25% of HCCs, β-catenin and Axin1 mutations are observed [69,81] .

               Notch signaling pathway
               The Notch canonical signaling plays an important role in cell differentiation, proliferation and apoptosis,
               as well as in stem cell and HPCs maintenance [31,71,82,83] . Moreover, Notch signaling is implicated in bile duct
                                        [84]
               morphogenesis (reviewed in ), and dysfunction in this pathway may result in reduced detoxification,
   93   94   95   96   97   98   99   100   101   102   103